Novo Nordisk participates in USD 57m financing round at strategic partner

Beta Bionics, a partner of both Novo Nordisk and Zealand Pharma, has closed a USD 57m series C financing round with participation from existing investors, including Novo Nordisk, and one newcomer.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

A partner of Danish pharmaceutical firm Novo Nordisk, US-based Beta Bionics, has been on a successful capital hunt, bringing in USD 57m in a series C financing round, the company informs in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now